SOCIETY: AGA This session will feature cutting-edge research on the multifaceted aspects of Clostridioides difficile colitis, presenting the latest findings in pathogenesis and innovative therapeutic approaches. Attendees will gain valuable insights into the molecular and immunological aspects of C. difficile infection. The session will also address emerging therapeutic options using different forms of fecal microbiota transplanation and defined microbial consortia.

Presentation:

SINGLE-CELL RNA PROFILING AND HIGH-THROUGHPUT SCREENING DISCOVERED MACROPHAGE INFLAMMATORY PROTEIN 1 ALPHA AND HISTAMINE 1 RECEPTOR AS KEY PATHWAYS IN C. DIFFICILE INFECTION.

EFFECTS OF LYOPHILIZED FECAL FILTRATE COMPARED TO LYOPHILIZED DONOR STOOL IN THE TREATMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: A MULTI-CENTER, DOUBLE-BLINDED RANDOMIZED TRIAL

PATIENT OUTCOMES OF INTESTINAL MICROBIOTA TRANSPLANTATION FOR SEVERE AND FULMINANT CLOSTRIDIOIDES DIFFICILE INFECTION: RESULTS FROM A NATIONAL REGISTRY.

ORAL CAPSULE FMT COMBINED WITH BEZLOTOXUMAB IS A SUCCESSFUL RESCUE PROTOCOL FOLLOWING FAILURE OF FMT ALONE IN TREATMENT OF RECURRENT C. DIFFICILE INFECTION

RECOVERY OF MICROBIOME FUNCTIONAL PATHWAYS INVOLVED IN STICKLAND FERMENTATION IN PATIENTS RECEIVING VE303, A DEFINED BACTERIAL CONSORTIUM FOR CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)

CLOSTRIDIOIDES DIFFICILE INFECTION INDUCES MUC5AC EXPRESSION IN MICE AND HUMANS AND ALTERS THE MUCOSAL GLYCAN COMPOSITION

A MULTIVALENT NUCLEOSIDE-MODIFIED MRNA-LNP VACCINE FOR CLOSTRIDIODIES DIFFICILE

Rachel Stubler

Appearances